Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor.

Abstract In this Letter we describe the discovery of potent, selective, and orally active aminopurine JNK inhibitors. Improving the physico-chemical properties as well as increasing the potency and selectivity of a subseries with rat plasma exposure, led to the identification of four structurally diverse inhibitors. Differentiation based on PK profiles in multiple species as well as activity in a chronic efficacy model led to the identification of 1 ( CC-930 ) as a development candidate, which is currently in Phase II clinical trial for IPF.